Efavirenz clinical trials
Efavirenz is named as an intervention in 4 current clinical trials in our China and Canada registers. 3 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Xuanwu Hospital, Beijing (1). The most-studied condition is Creutzfeldt-Jakob Disease. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
Where Efavirenz is approved
All regulators →Of the three regulators tracked here, the first to approve Efavirenz was the US, on 17 Sep 1998. It is approved in 3 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Efavirenz
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Efavirenz works
All drug targets →- Human immunodeficiency virus type 1 reverse transcriptase inhibitor InhibitorChEMBL only
- AIDSPhase 3
- Creutzfeldt Jacob diseasePhase 3
- Kaposi's sarcomaPhase 3
- SepsisPhase 3
- Hepatitis B virus infectionPhase 3
- Hepatitis C virus infectionPhase 3
- Inherited lipid metabolism disorderPhase 3
- PneumoniaPhase 3
- TuberculosisPhase 3
- Viral loadPhase 3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL223228, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 11287, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Efavirenz
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 10 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- EUEuropean Union: Efavirenz Teva (generic)EMA product information: package leaflet and summary of product characteristics in every EU language.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Efavirenz
- ATC code
- J05AG03
- ChEMBL
- CHEMBL223228
- DrugBank
- DB00625
- PubChem CID
- 64139
- CAS number
- 154598-52-4
- FDA UNII
- JE6H2O27P8
- Wikidata
- Q422645
- Wikipedia
- Efavirenz
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Efavirenz
4 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Efavirenz for the Treatment of Creutzfeldt-Jakob Disease
NCT07482085 · ClinicalTrials.gov ↗ · Creutzfeldt-Jakob Disease
|
Phase 3 | Recruiting | Xuanwu Hospital, Beijing | China |
|
Reverse Triple Negative Immune Resistant Breast Cancer
NCT05076682 · ClinicalTrials.gov ↗ · Triple-negative Breast Cancer
|
Phase 2 | Recruiting | Fudan University | China |
|
The T Cell Activator of Cell Killing ("TACK") IT ON" STUDY
NCT06823596 · ClinicalTrials.gov ↗ · Hiv
|
Not applicable | Recruiting | University of Toronto | Canada |
|
A Single-center, Randomized, Open-label, Parallel-design Clinical Study to Evaluate the Pharmacokinetic Effects of Itraconazole, Fluconazole or Efavirenz on a Single Dose of Clifutinib in Healthy Participants
NCT07341672 · ClinicalTrials.gov ↗ · Healthy Adult Subject
|
Phase 1 | Not yet open | Sunshine Lake Pharma Co., Ltd | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Efavirenz in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Efavirenz. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to a Regimen of Broadly Neutralizing
Antibodies Teropavimab and Zinlirvimab in Combination with Capsid Inhibitor Lenacapavir Twice Yearly in Virologically Suppressed Adults with HIV-1 Infection on Stable Oral Treatment Regimens
2025-524336-19-00 · Virus Diseases
|
Phase 3 | Ongoing | Gilead Sciences Inc | Poland, Italy, France + 3 more |
Efavirenz across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
10 single-substance products containing Efavirenz on the HPRA medicines list.
- Efavirenz Teva 600 mg film-coated tabletsTeva B.V. · EU/1/11/742/001-010
- STOCRINMerck Sharp & Dohme BV, · EU/1/99/111/001
- STOCRINMerck Sharp & Dohme BV, · EU/1/99/111/002
- STOCRIN 200 mg film-coated tabletsMerck Sharp & Dohme BV, · EU/1/99/111/011
- STOCRIN 30 mg/mL oral solutionMerck Sharp & Dohme BV, · EU/1/99/111/005
Supply shortages
No entry for Efavirenz in the EMA, FDA or German BfArM shortage lists we track.
Conditions studied with Efavirenz
4 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Xuanwu Hospital, Beijing | 1 |
| Sunshine Lake Pharma Co., Ltd | 1 |
| Fudan University | 1 |
| University of Toronto | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 3 | 2 |
| Clinical trials in Canada | 1 | 1 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Efavirenz trials
How many clinical trials are testing Efavirenz?
4 current trials in our China and Canada registers name Efavirenz as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Efavirenz trials recruiting patients?
Yes. 3 of the 4 trials are recruiting: 2 with sites in China and 1 with sites in Canada. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Efavirenz clinical trials?
Xuanwu Hospital, Beijing (1), Sunshine Lake Pharma Co., Ltd (1), Fudan University (1) and University of Toronto (1). The number in brackets is how many trials each organisation leads.
Is Efavirenz licensed in Ireland?
Yes. The HPRA medicines list includes 10 single-substance products containing Efavirenz, for example Efavirenz Teva 600 mg film-coated tablets (Teva B.V.). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Efavirenz shortage?
Not in the lists we track: Efavirenz has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Efavirenz works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Efavirenz works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Efavirenz (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.